NBW Capital LLC Makes New Investment in Johnson & Johnson (NYSE:JNJ)

NBW Capital LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJGet Rating) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,153 shares of the company’s stock, valued at approximately $204,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Family CFO Inc acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at $26,000. Steward Financial Group LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at $34,000. Joseph P. Lucia & Associates LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter valued at $38,000. Advocacy Wealth Management Services LLC boosted its holdings in shares of Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after purchasing an additional 67 shares in the last quarter. Finally, Gibson Wealth Advisors LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at $49,000. Institutional investors own 68.78% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,785,140. The disclosure for this sale can be found here. Corporate insiders own 0.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. SVB Leerink reduced their target price on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. UBS Group cut their price objective on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. The Goldman Sachs Group raised their price objective on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. Wells Fargo & Company raised their price objective on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a report on Wednesday, July 13th. Finally, Morgan Stanley raised their price objective on Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a report on Friday, July 8th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $189.89.

Johnson & Johnson Stock Up 1.0 %

Shares of JNJ opened at $174.59 on Thursday. The company has a market capitalization of $459.42 billion, a PE ratio of 25.41, a PEG ratio of 3.31 and a beta of 0.59. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The stock’s 50-day moving average price is $175.57 and its two-hundred day moving average price is $174.49. The company has a current ratio of 1.42, a quick ratio of 1.14 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The firm had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. During the same period in the previous year, the business earned $2.48 EPS. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. On average, analysts anticipate that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be given a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.59%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 65.79%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.